Abstract
Background
Gastrointestinal stromal tumor (GIST) is the most common sarcoma of the gastrointestinal tract. A retrospective study was done to evaluate the clinical and pathological features and the effect of adjuvant treatment with imatinib.
Method
The case records of 113 GIST patients were retrospectively reviewed and the clinicopathological features, treatments, and outcomes were recorded.
Results
There were 82 males and 31 females, with a median age of 51 years. All patients were symptomatic (mean duration 4 months) and abdominal pain was the most common symptom. The primary sites of GIST were small intestine (38), stomach (36), and others (39). The tumor diameter on imaging varied from 1 to 26 (mean 10.9) cm. Thirty percent of patients presented with metastasis. There was no association between tumor size and presence of metastasis (p = 0.9). Most common histology was spindle cell morphology followed by mixed spindle cell and epithelioid morphology. Seventy percent patients had high risk (HR) category as per Fletcher risk score. Fifty-three percent had curative resection, after which 34 % had adjuvant imatinib therapy. Recurrence rates were significantly lower in patients receiving adjuvant imatinib therapy (p = 0.003). No statistically significant association was noted between HR Fletcher score, Mib score >10, tumor size >10 cm, and the risk of recurrence (p = 0.29, 0.07, and 0.87, respectively). Liver was the most common site of metastasis. Side effects were tolerable and edema and fluid retention were the commonest.
Conclusion
Sites of GIST in Indian patients were different from those in western studies. Adjuvant imatinib therapy significantly reduced the risk of recurrence.
Similar content being viewed by others
References
Miettinen M, Majidi M, Lasota J. Pathology and diagnostic criteria of gastrointestinal stromal tumors [GISTs]: a review. Eur J Cancer. 2002;38 Suppl 5:S39–51.
Solis-Herruzo JA, Solis-Muñoz P. GISTs: from the molecular knowledge to the rational treatment. Rev Esp Enferm Dig. 2003;95:677–82.
Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33:459–65.
Nilsson B, Bumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era—a population-base study in western Sweden. Cancer. 2005;103:821–9.
Goettsch WG, Bos SD, Breekveldt-Postma N, et al. Incidence of gastrointestinal stromal tumors is underestimated: results of a nation-wide study. Eur J Cancer. 2005;41:2868–72.
Sircar K, Hewlett BR, Huizinga JD, et al. Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors. Am J Surg Pathol. 1999;23:377–89.
Sanders KM. A case of interstitial cells of Cajal as pacemakers and mediators of neurotransmission in the gastrointestinal tract. Gastroenterology. 1996;111:492–515.
Miettinen M, Lasota J. Gastrointestinal stromal tumors—definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. 2001;438:1–12.
Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577–80.
Bucher P, Villiger P, Egger J, et al. Management of gastrointestinal stromal tumors: from diagnosis to treatment. Swiss Med Wkly. 2004;134:145–53.
Rajappa S, Muppavarapu KM, Uppin S, Digumarti R. Gastrointestinal stromal tumors: a single institution experience of 50 cases. Indian J Gastroenterol. 2007;26:225–9.
Roberts P, Eisenberg B. Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease. Eur J Cancer. 2002;38:S37–8.
Connolly E, Gaffney E, Reynolds J. Gastrointestinal stromal tumors. Br J Surg. 2003;90:1178–86.
Dematteo RP, Heinrich MC, El-Rifai WM, et al. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol. 2002;33:466–77.
Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472–80.
Joensuu H, Fletcher C, Dimitrijevic S, et al. Management of malignant gastrointestinal stromal tumors. Lancet Oncol. 2002;3:655–64.
Verweij J, Casali P, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumors with high-dose imatinib: randomized trial. Lancet. 2004;364:1127–34.
Rubin BP, Singer S, Tsao C, et al. KIT activation is an ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 2001;61:8118–21.
Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumor: a randomized, double blind, placebo controlled trial. Lancet. 2009;373:1097–104.
Vij M, Agrawal V, Kumar A, Pandey R. Gastrointestinal stromal tumors: a clinicopathological and immunohistochemical study of 121 cases. Indian J Gastroenterol. 2010;29:231–6.
Singh A, Chatterjee P, Pai MC, Chacko RT. Gastrointestinal stromal tumours: a clinico-radiologic review from a single centre in South India. J Med Imaging Radiat Oncol. 2009;53:522–9.
Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.
Terada T. Gastrointestinal stromal tumor of the digestive organs: a histopathologic study of 31 cases in a single Japanese institute. Int J Clin Exp Pathol. 2009;3:162–8.
Cho MY, Sohn JH, Kim JM, et al. Current trends in the epidemiological and pathological characteristics of gastrointestinal stromal tumors in Korea, 2003–2004. J Korean Med Sci. 2010;25:853–62.
Fujimoto Y, Nakanishi Y, Yoshimura K, Shimoda T. Clinicopathologic study of primary malignant gastrointestinal stromal tumor of the stomach, with special reference to prognostic factors: analysis of results in 140 surgically resected patients. Gastric Cancer. 2003;6:39–48.
Demetri GD, von Mehren M, Antonescu CR, et al. NCCN task force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw. 2010;8 Suppl 2:S1–41.
Acknowledgments
We are thankful to Dr. Mukta Ramadwar for her valuable help and advice in this study.
Conflict of interest
None
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bhalgami, R., Manish, K., Patil, P. et al. Clinicopathological study of 113 gastrointestinal stromal tumors. Indian J Gastroenterol 32, 22–27 (2013). https://doi.org/10.1007/s12664-012-0273-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12664-012-0273-2